Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. Among authors: tiraboschi j. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Predictors of poor health-related quality of life among people living with HIV aged ≥60 years in the PISCIS cohort: Findings from the Vive+ project.
Bruguera A, Egea-Cortés L, Mesías-Gazmuri J, Palacio-Vieira J, Forero CG, Miranda C, Saumoy M, Fernández E, Navarro G, Orti A, Miró JM, Casabona J, Reyes-Urueña J; PISCS Study Group. Bruguera A, et al. HIV Med. 2024 Apr;25(4):424-439. doi: 10.1111/hiv.13590. Epub 2023 Dec 13. HIV Med. 2024. PMID: 38092529
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.
de Lazzari E, Negredo EB, Domingo P, Tiraboschi JM, Ribera E, Abdulghani N, Alba V, Fernández-Arroyo S, Viladés C, Peraire J, Gatell JM, Blanco JL, Vidal F, Rull A, Martinez E. de Lazzari E, et al. Among authors: tiraboschi jm. J Antimicrob Chemother. 2024 May 2;79(5):1133-1141. doi: 10.1093/jac/dkae083. J Antimicrob Chemother. 2024. PMID: 38546974 Free PMC article. Clinical Trial.
Early Detection of Cancer and Precancerous Lesions in Persons with HIV through a Comprehensive Cancer Screening Protocol.
Gutiérrez F, López L, Galera C, Tiraboschi JM, Portu J, García-Fraile L, García Del Toro M, Bernal E, Rivero A, García-Abellán J, Flores J, González-Cordón A, Martínez O, Bravo J, Rosado D, Montero M, Sirera G, Torralba M, Galindo MJ, Macías J, Gónzalez I, Boix V, Vivancos MJ, Dios P, Blanco JR, Padilla S, Fernández-González M, Gutiérrez Ortiz de la Tabla A, Martínez E, Masiá M; IMPAC-Neo Study Group. Gutiérrez F, et al. Among authors: tiraboschi jm. Clin Infect Dis. 2024 Jul 3:ciae359. doi: 10.1093/cid/ciae359. Online ahead of print. Clin Infect Dis. 2024. PMID: 38959300
How can we optimize the diagnostic and therapeutic approach to pneumonia? Expert opinion-based recommendations.
Fernández-Ruiz M, Castón JJ, Del Pozo JL, Carratalà J, Fortún J, Salavert M, Torre-Cisneros J, Aguado JM; members of the OPENIN (Optimización de procesos clínicos para el diagnóstico y tratamiento de infecciones) Group; Fernández Cruz A, Ventura A, Loeches B, Dueñas C, Tomás C, Navarro D, Oltra R, Resino-Foz E, García Vázquez E, Míguez E, Merino E, Braojos F, Martínez FJ, López-Medrano Pérez F, Machuca I, Cobo J, López Contreras J, Reguera JM, Ruiz Mesa JD, Tiraboschi J, Abella L, Masiá M, Del Toro López MD, Díaz López MD, Carrasco-Antón N, Merchante N, Muñoz P, Torres R, Rodríguez R, Mata-Forte T, Abril V. Fernández-Ruiz M, et al. Among authors: tiraboschi j. Enferm Infecc Microbiol Clin (Engl Ed). 2024 Oct;42(8):442-452. doi: 10.1016/j.eimce.2024.07.001. Epub 2024 Aug 6. Enferm Infecc Microbiol Clin (Engl Ed). 2024. PMID: 39112116 Free article. Review.
The persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function.
Garrido-Rodríguez V, Bulnes-Ramos Á, Olivas-Martínez I, Pozo-Balado MDM, Álvarez-Ríos AI, Gutiérrez F, Izquierdo R, García F, Tiraboschi JM, Vera-Méndez F, Peraire J, Rull A, Pacheco YM; CoRIS cohort. Garrido-Rodríguez V, et al. Among authors: tiraboschi jm. J Microbiol Immunol Infect. 2024 Dec;57(6):854-867. doi: 10.1016/j.jmii.2024.08.007. Epub 2024 Aug 22. J Microbiol Immunol Infect. 2024. PMID: 39209566 Free article.
Epidemiological, clinical and mortality trends in people with HIV over 60 years in the PISCIS population-based cohort from Catalonia and Balearic Islands.
Bruguera A, Nomah DK, Moreno-Fornés S, Martinez E, Negredo E, Tiraboschi J, Navarro J, Domingo P, Fanjul F, Villoslada A, Peraire J, Jaen A, Miró JM, Casabona J, Reyes-Urueña J; and the PISCIS Study Group. Bruguera A, et al. Among authors: tiraboschi j. AIDS. 2025 Jan 1;39(1):64-74. doi: 10.1097/QAD.0000000000004018. Epub 2024 Sep 19. AIDS. 2025. PMID: 39639721
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2024 Dec 23:dkae456. doi: 10.1093/jac/dkae456. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39710424
94 results